Developing Practical Therapeutic Strategies that Target Protein SUMOylation
Authors:
Open Access
- 11 June 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 20 (9) , 960-969
Abstract
Post-translational modification by small ubiquitin-like modifier (SUMO) has emerged as a global mechanism for the control and integration of a wide variety of biological processes through the regulation of protein activity, stability and intracellular localization. As SUMOylation is examined in greater detail, it has become clear that the process is at the root of several pathologies including heart, endocrine, and inflammatory disease, and various types of cancer. Moreover, it is certain that perturbation of this process, either globally or of a specific protein, accounts for many instances of congenital birth defects. In order to be successful, practical strategies to ameliorate conditions due to disruptions in this post-translational modification will need to consider the multiple components of the SUMOylation machinery and the extraordinary number of proteins that undergo this modification.Keywords
Funding Information
- National Institutes of Health (GM38200)
This publication has 132 references indexed in Scilit:
- Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunctionJournal of Molecular and Cellular Cardiology, 2012
- SUMO1-dependent modulation of SERCA2a in heart failureNature, 2011
- Proteasome inhibition induces α-synuclein SUMOylation and aggregate formationJournal of the Neurological Sciences, 2011
- Active site remodelling accompanies thioester bond formation in the SUMO E1Nature, 2010
- Planar cell polarity pathway genes and risk for spina bifidaAmerican Journal of Medical Genetics Part A, 2010
- Sumoylation of amyloid precursor protein negatively regulates Aβ aggregate levelsBiochemical and Biophysical Research Communications, 2008
- Transient early embryonic expression of Nkx2‐5 mutations linked to congenital heart defects in human causes heart defects in Xenopus laevisDevelopmental Dynamics, 2007
- Drug discovery in the ubiquitin–proteasome systemNature Reviews Drug Discovery, 2006
- Insights into E3 ligase activity revealed by a SUMO–RanGAP1–Ubc9–Nup358 complexNature, 2005
- GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5Nature, 2003